MetaADEDB 2.0 @ LMMD
nilvadipine
(FAIIFDPAEUKBEP-UHFFFAOYSA-N)
Structure
SMILES
COC(=O)C1=C(C#N)NC(=C(C1c1cccc(c1)[N+](=O)[O-])C(=O)OC(C)C)C
Type(s)
Approved; Investigational
ATC code(s)
C08CA10
Molecular Formula:
C19H19N3O6
Molecular Weight:
385.371
Log P:
3.3099
Hydrogen Bond Acceptor:
6
Hydrogen Bond Donor:
1
TPSA:
134.24
CAS Number(s):
75530-68-6
Synonym(s)
1.
nilvadipine
2.
5-isopropyl-3-methyl-2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinecarboxylate
3.
Escor
4.
FR 34235
5.
FR-34235
6.
Nivadil
External Link(s)
MeSHC035100
PubChem Compound4494
BindingDB50103634
50367849
ChEBI31911
CHEMBLCHEMBL517427
DrugBankDB06712
DrugCentral1934
IUPHAR/BPS Guide to PHARMACOLOGY10160
KEGGdr:D01908
Therapeutic Target DatabaseD06GRK
D01OKE
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1AbscessOFFSIDES
2Activated partial thromboplastin time shortenedOFFSIDES
3AdenocarcinomaOFFSIDES
4Alanine Aminotransferase IncreasedOFFSIDES
5Altered state of consciousnessOFFSIDES
6Ankle FractureOFFSIDES
7AnorexiaOFFSIDES
8AnosmiaOFFSIDES
9Anticholinergic SyndromeOFFSIDES
10Aortic AneurysmOFFSIDES
11ApathyOFFSIDES
12ApneaOFFSIDES
13Arteriosclerosis ObliteransOFFSIDES
14AsthmaOFFSIDES
15Atrial tachycardiaOFFSIDES
16Bilirubin conjugated increasedOFFSIDES
17Blood creatine phosphokinase increasedOFFSIDES
18Blood creatinine increasedOFFSIDES
19Blood electrolytes abnormalOFFSIDES
20Blood fibrinogen increasedOFFSIDES
21Blood glucose abnormalOFFSIDES
22Blood lactate dehydrogenase increasedOFFSIDES
23Blood potassium increasedOFFSIDES
24Body TemperatureOFFSIDES
25Brain DeathOFFSIDES
26Brain Ischemia8875450CTD
27Cerebral ThrombosisOFFSIDES
28Chest PainOFFSIDES
29CirrhosisOFFSIDES
30Cold sweatOFFSIDES
31CyanosisOFFSIDES
32Depressed Level of ConsciousnessOFFSIDES
33DiarrheaOFFSIDES
34Disseminated Intravascular CoagulationOFFSIDES
35DysuriaOFFSIDES
36Echocardiogram abnormalOFFSIDES
37Erythema MultiformeOFFSIDES
38Gamma-Glutamyltransferase IncreasedOFFSIDES
39Gastric ulcerOFFSIDES
40GastroenteritisOFFSIDES
41Hepatic necrosisOFFSIDES
42HydrocephalusOFFSIDES
43HydronephrosisOFFSIDES
44HyperventilationOFFSIDES
45HypokinesiaOFFSIDES
46Hypotension8875450CTD
47HypoxiaOFFSIDES
48IncontinenceOFFSIDES
49Infection in an immunocompromised hostOFFSIDES
50IntubationOFFSIDES
51Kidney Diseases7533848CTD
52Kidney FailureOFFSIDES
53Large intestine perforationOFFSIDES
54Leukocyte alkaline phosphatase increasedOFFSIDES
55Leukopenia neonatalOFFSIDES
56Lichen PlanusOFFSIDES
57Lymphocyte count decreasedOFFSIDES
58Lymphocyte percentage decreasedOFFSIDES
59LymphomaOFFSIDES
60MelanosisOFFSIDES
61Musculoskeletal stiffnessOFFSIDES
62MyelodysplasiaOFFSIDES
63OliguriaOFFSIDES
64PO2 decreasedOFFSIDES
65PanniculitisOFFSIDES
66PeriarthritisOFFSIDES
67Pericardial effusionOFFSIDES
68PlasmapheresisOFFSIDES
69PleurisyOFFSIDES
70Polymyalgia RheumaticaOFFSIDES
71Post procedural complicationOFFSIDES
72QuadriplegiaOFFSIDES
73Renal cystOFFSIDES
74Renal tubular necrosisOFFSIDES
75Respiratory FailureOFFSIDES
76Retinal vascular occlusionOFFSIDES
77Ruptured diverticulum of colonOFFSIDES
78Septic ShockOFFSIDES
79Sick Sinus SyndromeOFFSIDES
80Skin necrosisOFFSIDES
81SnoringOFFSIDES
82TetanyOFFSIDES
83Transaminases increasedOFFSIDES
84Treatment related secondary malignancyOFFSIDES
85Urine potassium increasedOFFSIDES
86Vocal Cord ParalysisOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.